Zhejiang Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ZHEJIANG
ZHEJIANG has twenty-four approved drugs.
There are two tentative approvals on ZHEJIANG drugs.
Drugs and US Patents for Zhejiang
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Poly Pharm | AZITHROMYCIN | azithromycin | FOR SUSPENSION;ORAL | 217036-001 | Jul 27, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zhejiang Jingxin | TICAGRELOR | ticagrelor | TABLET;ORAL | 219006-002 | Mar 24, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zhejiang Novus Pharm | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | POWDER;INTRAVENOUS, ORAL | 210274-001 | Jan 20, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Zhejiang Novus Pharm | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | POWDER;INTRAVENOUS, ORAL | 210274-007 | Aug 1, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Zhejiang Yongtai | GABAPENTIN | gabapentin | CAPSULE;ORAL | 213603-002 | Aug 17, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zhejiang Jutai Pharm | BUPROPION HYDROCHLORIDE | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 211200-002 | Apr 29, 2020 | AB3 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

